# US 2026/0077066 A1 · Receptor-targeting conjugate with an effective pharmacokinetic profile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077066 A1
- Document ID: US20260077066A1
- Status: Published application
- Kind: A1
- Application number: 19/395,728
- Filed: 2025-11-20
- Published: 2026-03-19
- Earliest claimed: 2019-07-16
- Assignees: Fluoguide A/S
- Applicants: Fluoguide A/S
- Inventors: Andreas KJÆR; Morten ALBRECHTSEN
- Web page: https://patentgrep.com/patent/US20260077066A1

## CPC

- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0034: {Indocyanine green, i.e. ICG, cardiogreen}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention describes a receptor-targeting conjugate comprising a fluorophore; a molecule, e.g. a peptide, binding to the receptor; and—a linker group which covalently links the fluorophore to the molecule binding to the receptor, wherein the conjugate is adapted to be administered intravenously into a human or animal body, and provide an effective pharmacokinetic profile with reference to inter alia receptor binding affinity and removal from plasma.

## Claims

### Claim 1

A method comprising using a receptor-targeting conjugate comprising:
a fluorophore;
a molecule binding to the receptor; and
a linker group which covalently links the fluorophore to the molecule binding to the receptor,
said method comprising:
administering the receptor-targeting conjugate into a human or animal body, and thereby
providing receptor binding at least within 4,500 minutes;
removal from plasma making the conjugate bound to the receptor visible, measured as plasma half-life which is the time it takes for the concentration in plasma to be reduced with 50%, and wherein the plasma half-life has a maximum of 4,500 minutes;
providing receptor binding lasting at least 30 minutes;
proving a receptor binding affinity, being the time it takes to reach the desired receptor binding, the lasting of the receptor binding and plasma half-life translating into a TBR (tumor-to-background ratio) of at least 1.5 and reaching that level within 4,500 minutes after administration into the human or animal body; and
ensuring this level of TBR of at least 1.5 at least 30 minutes after that this level has been obtained.

### Claim 2 (depends on 1)

The method according to claim 1, wherein:
the providing receptor binding is at least within 600 minutes;
the plasma half-life has a maximum of 1,200 minutes;
the receptor binding is at least within 30 minutes; and
the TBR of at least 1.5 is reached within 600 minutes after administration into the human or animal body.

### Claim 3 (depends on 2)

The method according to claim 2, wherein:
the providing receptor binding is at least within 300 minutes; and
the TBR of at least 1.5 is reached within 300 minutes after administration into the human or animal body.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the conjugate is a peptide conjugate and wherein the peptide conjugate comprises a peptide binding to the receptor.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the peptide is chosen from the group consisting of:
-Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser;
and
-Asp-Cha-Phe- Ser-Arg -Tyr-Leu-Trp-Ser-NH2.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the targeting receptor is a urokinase Plasminogen Activator Receptor (uPAR), a tissue factor (TF), an epidermal growth factor receptor (EGFR), a prostate-specific membrane antigen (PSMA), a Vascular Endothelial Growth Factor (VEGF), a Folate receptor, a matrix metalloproteinase-2 (MMP-2), a membrane type-I MMP, transmembrane inhibitor of metalloproteinase-2 (TIMP2), CIC-3 chloride ion channels, disaccharides and other glycans or glyco-phosphatidylinositol (GPI)-anchored cell membrane receptors.

### Claim 7 (depends on 1)

The method according to claim 1, wherein receptor affinity is measured as IC50, wherein the ligand/receptor binding affinity is measured at a wavelength of 320 nM or less.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the receptor-targeting conjugate has a sensitivity for detection of cancer tissue of at least 60%.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the receptor-targeting conjugate has a sensitivity for detection of cancer tissue of at least 80%.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the fluorophore is a near-infrared I fluorophore or a near-infrared II fluorophore.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the fluorophore is IRDye800CW or indocyanin green (ICG).

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method includes measuring receptor binding affinity in vitro using a receptor affinity assay.

### Claim 13 (depends on 12)

The method according to claim 12, wherein receptor binding occupancy reaches at least 5% measured in vitro using a receptor affinity assay.

### Claim 14 (depends on 12)

The method according to claim 12, wherein receptor binding occupancy reaches at least 25% measured in vitro using a receptor affinity assay.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the method is performed in cancer therapy or diagnosis.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the method is performed in cancer therapy or diagnosis using optical imaging/-fluorescence imaging (FLI) of cancer.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the receptor-targeting conjugate is used together with at least one pharmaceutically acceptable carrier or excipient in a pharmaceutical composition.

### Claim 18 (depends on 1)

The method according to claim 1, said method also comprising:
binding of the fluorophore to the receptor with a receptor binding occupancy of at least 5%, measured in vitro using a receptor affinity assay, and a maximum of the receptor binding within 4,500 minutes after administration into the human or animal body, resulting in the TBR of at least 1.5 is reached within 4,500 minutes after administration into the human or animal body; and
using the receptor-targeting conjugate in cancer therapy or diagnosis.

### Claim 19 (depends on 1)

The method according to claim 1, said method comprising:
using the receptor-targeting conjugate in cancer therapy or diagnosis using optical imaging/fluorescence imaging (FLI) of cancer.

### Claim 20 (depends on 1)

The method according to claim 1, where the method involves optical imaging, said method comprising the steps of:
(i) administering of the receptor-targeting conjugate accumulating in a target tissue,
(ii) allowing time for the receptor-targeting conjugate to accumulate in the target tissue and establishing a receptor binding within 4,500 minutes after administration into the human or animal body, and with a TBR of at least 1.5 which TBR level is reached within 4,500 minutes after administration into the human or animal body;
(iii) illuminating the target tissue with light of a wavelength absorbable by the fluorophore; and
(iv) detecting fluorescence emitted by the fluorophore and forming an optical image of the target tissue.
